SOURCE: Goldman Small Cap Research, Inc.

June 18, 2013 09:06 ET

New Malaria Crisis Presents Opportunity for Plandai

BALTIMORE, MD--(Marketwired - Jun 18, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that a recent proliferation of fake malaria and other drugs on the African continent presents a major opportunity for Plandai Biotechnology Inc. (OTCQB: PLPL). Plandai is a developer of highly bioavailable, phytonutrient rich extracts (like EGCG), which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.

In a recent feature story published in The Atlantic in early June, an estimated one-third of all malaria drugs in some African countries may be counterfeit or sub-standard. This crisis is a potential disaster for the hundreds of millions people living in areas at risk of malaria transmission in Africa and it could prompt a spike in the estimated 600,000 deaths from the disease this year occurring in the African Region.

However, Plandai may be able to aid in this situation. In a recent study, the Company's Phytofare™ Catechin Extract proved effective in killing the malaria parasite, plasmodium falciparum. In the study, the single and most dominant catechin -- Epigallocatechin Gallate (EGCG) -- was isolated from Plandai's Phytofare™ extract and its effectiveness compared in killing the P. falciparum parasite against a purified EGCG extract.

If the Company is successful in developing a treatment or preventive vehicle for malaria, it could be a very profitable and very swift game-changer for the Company given its South Africa plantation and botanical-based therapeutic and go a long way toward cost-effectively eliminating one of the world's most severe health issues. Plus, given the form and type of treatment, it is unlikely that counterfeit or false Plandai products would be produced, which would provide both a clinical and ethical benefit to those at risk.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit

Contact Information